Atlas One · Host Biology · Scale 07 — System

Neuroendocrine Tumors

Neuroendocrine tumors arise from diffuse neuroendocrine cells; well-differentiated G1/G2 NETs are treated with SSA (octreotide/lanreotide) and lutetium-177 DOTATATE (NETTER-1); everolimus (RADIANT) and sunitinib approved for pNET; poorly differentiated NEC treated as SCLC.

Also known as: neuroendocrine tumors, NET, NEN, carcinoid tumor, pNET, pancreatic NET, GEP-NET, neuroendocrine carcinoma, NEC, PRRT, Lutathera, DOTATATE

Scale 07 — SystemScale
draftStatus
2026-06-06Last Reviewed
This is an auto-generated stub page built from atlas entry frontmatter. A richer hand-crafted page is planned. See the atlas source for the full entry including detailed body sections.
neuroendocrine-tumors

Neuroendocrine Tumors

Neuroendocrine tumors arise from diffuse neuroendocrine cells; well-differentiated G1/G2 NETs are treated with SSA (octreotide/lanreotide) and lutetium-177 DOTATATE (NETTER-1); everolimus (RADIANT) and sunitinib approved for pNET; poorly differentiated NEC treated as SCLC.

Entry Metadata

FieldValue
IDneuroendocrine-tumors
NameNeuroendocrine Tumors
Statusdraft
Last reviewed2026-06-06
Atlas01-human
Scale07-system

Cross-Atlas Connections

connects-toSstr2 connects-toMtor connects-toVegf connects-toGlucagon connects-toMen1 Syndrome connects-toSerotonin connects-toPancreas connects-toNeuroblastoma connects-toSmall Intestine connects-toMen4 Syndrome

Sources